Crinetics Pharmaceuticals Inc Stock Prediction and Forecast [CRNX]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 26 Sept 2025, 03:21 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for Crinetics Pharmaceuticals Inc Stock Prediction and Forecast [CRNX]](https://i.ytimg.com/vi/DJJNZQ9ZPis/hqdefault.jpg)
AI-generated source summary
The video presents a stock analysis for Crinetics Pharmaceuticals (CRNX) as of September 2025. The system ranks CRNX as a buy candidate, assigning a score of 2.34. Since September 18, 2025, CRNX has gained 1.16%, averaging 0.19% daily. In the short term, the stock sits within an upward trend with potential increases. A 3-month trend suggests a 16.04% change. Twelve-month analysis projects a negative change of -46.82%, fluctuating between -83.59% and -48.11%, with the stock between 5.89 and 18.62. The last trading day closed at $35.89, gaining 2.02%, fluctuating 6.81% between $34.52 and $36.87. Volume increased with price on the last trade, reaching 2M shares, indicating a positive signal. The highest price in the past 52 weeks was $62.53. The short term moving averages suggest a sell. A pivot point has fallen -1.67% with a 3-month MACD suggesting a sell signal. Support is just below today’s price, $33.91 and $30.99. Volatility has indicated daily medium risk movements of 5.54%.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.